| Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis |
ENVASARC, NCT04480502: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma |
|
|
| Active, not recruiting | 2 | 207 | Europe, US | Envafolimab, KN035, Ipilimumab, Yervoy | Tracon Pharmaceuticals Inc. | Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | 10/24 | 10/24 | | |
ChiCTR2200062943: Envafolimab combined with AI for the first-line treatment of advanced soft tissue sarcoma: a prospective, open-label, single arm, single-center clinical study |
|
|
| Not yet recruiting | 2 | 30 | | Envafolimab combined with AI | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Partly self-funded, partly provied by simcere. | Soft tissue sarcoma | | | | |
NCT05941325: A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 20 | RoW | fruquintinib, Envafolimab | Shanghai 6th People's Hospital | Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma | 12/25 | 12/26 | | |
NCT05722977: Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients |
|
|
| Not yet recruiting | 2 | 45 | NA | Surufatinib + envafolimab | Peking Union Medical College Hospital | Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients | 02/26 | 02/27 | | |
NCT05448820: YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma |
|
|
| Active, not recruiting | 1/2 | 15 | US | YH001, Envafolimab, KN035, Doxorubicin | Tracon Pharmaceuticals Inc. | Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma | 11/23 | 09/25 | | |
